Dibucaine: Difference between revisions

Jump to navigation Jump to search
No edit summary
m (Protected "Dibucaine": Bot: Protecting all pages from category Drug ([Edit=Allow only administrators] (indefinite) [Move=Allow only administrators] (indefinite)))
 
(5 intermediate revisions by one other user not shown)
Line 4: Line 4:
|genericName=Dibucaine
|genericName=Dibucaine
|aOrAn=a
|aOrAn=a
|drugClass=Local analgesic ointment
|drugClass=[[Local analgesia|Local analgesic ointment]]
|indicationType=treatment
|indicationType=treatment
|indication=pain and itching due to hemorrhoids or other anorectal disorders, sunburn, minor burns, minor cuts
|indication=[[pain]] and [[itching]] due to [[hemorrhoids]] or other [[Anus|anorectal disorders]], [[Sunburn]], [[Burn|minor burns]], [[Wound|minor cuts]]
|adverseReactions=unusual warmth or flushing of skin
|adverseReactions=[[Rash|unusual warmth or flushing of skin]], [[Contact dermatitis]], [[Photosensitivity]]


<!--Black Box Warning-->
|blackBoxWarningTitle=<span style="color:#FF0000;">ConditionName: </span>
|blackBoxWarningBody=<i><span style="color:#FF0000;">ConditionName: </span></i>
* Content


<!--Adult Indications and Dosage-->
<!--Adult Indications and Dosage-->
Line 19: Line 14:
<!--FDA-Labeled Indications and Dosage (Adult)-->
<!--FDA-Labeled Indications and Dosage (Adult)-->
|fdaLIADAdult=====Indications====
|fdaLIADAdult=====Indications====
temporarily relieves pain and itching due to:  
* temporarily relieves pain and itching due to:  


- hemorrhoids or other anorectal disorders - sunburn - minor burns - minor cuts  
:* [[hemorrhoids]] or other [[Anus|anorectal disorders]], [[sunburn]], [[Burn|minor burns]], [[Wound|minor cuts]]
- scrapes - insect bites - minor skin irritation  
:* scrapes, [[Insect Bites]], [[Irritation|minor skin irritation]]


====Dosage====
====Dosage====
Directions   
=====Directions=====  


- if possible clean the affected area with mild soap and warm water and rinse thoroughly  
* if possible clean the affected area with mild soap and warm water and rinse thoroughly  
- gently dry by patting or blotting with toilet tissue or a soft cloth before applying  
* gently dry by patting or blotting with toilet tissue or a soft cloth before applying  


Adults and children 12 and over - apply externally to the affected area up to 3 to 4 times a day.
* Adults and children 12 and over - apply externally to the affected area up to 3 to 4 times a day.
|offLabelAdultGuideSupport=There is limited information regarding <i>Off-Label Guideline-Supported Use</i> of {{PAGENAME}} in adult patients.
|offLabelAdultGuideSupport=There is limited information regarding <i>Off-Label Guideline-Supported Use</i> of {{PAGENAME}} in adult patients.


Line 39: Line 34:


<!--FDA-Labeled Indications and Dosage (Pediatric)-->
<!--FDA-Labeled Indications and Dosage (Pediatric)-->
|fdaLIADPed=Children under 2 - 12 years of age - ask a doctor  
|fdaLIADPed=* Children under 2 - 12 years of age - ask a doctor  


Infants under 2 years of age - DO NOT USE
* Infants under 2 years of age - DO NOT USE
|offLabelPedGuideSupport=There is limited information regarding <i>Off-Label Guideline-Supported Use</i> of {{PAGENAME}} in pediatric patients.
|offLabelPedGuideSupport=There is limited information regarding <i>Off-Label Guideline-Supported Use</i> of {{PAGENAME}} in pediatric patients.


Line 51: Line 46:
|warnings=* For external use only.  
|warnings=* For external use only.  


Allergy alert - certain persons san develop allergic reactions to ingredients in this product  
* Allergy alert - certain persons san develop allergic reactions to ingredients in this product  


Do not use  
* Do not use  
- in or near the eyes  
:* in or near the eyes  
- do not get into the eyes  
:* do not get into the eyes  
- in infants under 2 years of age  
:* in infants under 2 years of age  
- in large quantities, particularly over raw surfaces or blistered areas  
:* in large quantities, particularly over raw surfaces or blistered areas  
- do not put this product into rectum by using fingers or any mechanical device  
:* do not put this product into rectum by using fingers or any mechanical device  


Stop use and ask a doctor if  
* Stop use and ask a doctor if  
- condition worsens, or does not improve within 7 days  
:* condition worsens, or does not improve within 7 days  
- the symptom being treated does not subside or if redness, irritation, swelling, bleeding or other symptoms develop or increase  
:* the symptom being treated does not subside or if [[Erythema|redness]], [[irritation]], [[swelling]], [[bleeding]] or other symptoms develop or increase  


If pregnant or breast feeding, as a health care professional before use  
* If pregnant or breast feeding, as a health care professional before use  


Keep out of the reach of children. If swallowed, get medical help or contact a Poison Control Center right away  
* Keep out of the reach of children. If swallowed, get medical help or contact a Poison Control Center right away  


<!--Adverse Reactions-->
<!--Adverse Reactions-->
Line 72: Line 67:
<!--Clinical Trials Experience-->
<!--Clinical Trials Experience-->
|clinicalTrials=There is limited information regarding <i>clinical trial experience</i> of {{PAGENAME}} in the drug label.
|clinicalTrials=There is limited information regarding <i>clinical trial experience</i> of {{PAGENAME}} in the drug label.
|postmarketing=unusual warmth or flushing of skin
|postmarketing=* [[Rash|unusual warmth or flushing of skin]]
Chest pain
* [[Contact dermatitis]]
fast or irregular heartbeat
* [[Photosensitivity]]
tightness in the chest
* [[Chest pain]]
|drugInteractions=
* [[Tachycardia|fast or irregular heartbeat]]
 
* [[Chest pain|tightness in the chest]]
<!--Use in Specific Populations-->
* [[Hypersensitivity reaction]]
|drugInteractions=<!--Use in Specific Populations-->
|useInPregnancyFDA=* If pregnant or breast feeding, as a health care professional before use
|useInPregnancyFDA=* If pregnant or breast feeding, as a health care professional before use
|useInPregnancyAUS=* '''Australian Drug Evaluation Committee (ADEC) Pregnancy Category'''
|useInPregnancyAUS=* '''Australian Drug Evaluation Committee (ADEC) Pregnancy Category'''
Line 95: Line 91:


<!--Administration and Monitoring-->
<!--Administration and Monitoring-->
|administration=* topical
|administration=* [[topical]]
|monitoring=There is limited information regarding <i>Monitoring</i> of {{PAGENAME}} in the drug label.
|monitoring=There is limited information regarding <i>Monitoring</i> of {{PAGENAME}} in the drug label.


Line 104: Line 100:


<!--Overdosage-->
<!--Overdosage-->
|overdose=Keep out of the reach of children. If swallowed, get medical help or contact a Poison Control Center right away
|overdose=* Keep out of the reach of children. If swallowed, get medical help or contact a Poison Control Center right away
|drugBox=<!--Mechanism of Action-->
|drugBox={{Drugbox2
|mechAction=*
| Watchedfields = changed
| verifiedrevid = 460037677
| IUPAC_name = 2-butoxy-''N''-[2-(diethylamino)ethyl]quinoline-4-carboxamide
| image = Dibucaine wiki str.png
 
<!--Clinical data-->
| tradename = 
| Drugs.com = {{drugs.com|international|cinchocaine}}
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US = <!-- A / B / C / D / X -->
| pregnancy_category = 
| legal_AU = <!-- Unscheduled / S2 / S4 / S8 -->
| legal_UK = <!-- GSL / P / POM / CD -->
| legal_US = OTC
| legal_status = 
| routes_of_administration = topical, intravenous (equine euthanasia)
 
<!--Pharmacokinetic data-->
| bioavailability = 
| protein_bound = 
| metabolism = 
| elimination_half-life = 
| excretion = 
 
<!--Identifiers-->
| CASNo_Ref = {{cascite|correct|CAS}}
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 85-79-0
| ATC_prefix = C05
| ATC_suffix = AD04
| ATC_supplemental =  {{ATC|D04|AB02}} {{ATC|N01|BB06}} {{ATC|S01|HA06}} {{ATC|S02|DA04}}
| PubChem = 3025
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank = DB00527
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 2917
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = L6JW2TJG99
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D00733
| ChEBI_Ref = {{ebicite|correct|EBI}}
| ChEBI = 247956
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 1086
 
<!--Chemical data-->
| C=20 | H=29 | N=3 | O=2
| molecular_weight = 343.463 g/mol
| smiles = O=C(c1c2ccccc2nc(OCCCC)c1)NCCN(CC)CC
| InChI = 1/C20H29N3O2/c1-4-7-14-25-19-15-17(16-10-8-9-11-18(16)22-19)20(24)21-12-13-23(5-2)6-3/h8-11,15H,4-7,12-14H2,1-3H3,(H,21,24)
| InChIKey = PUFQVTATUTYEAL-UHFFFAOYAU
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C20H29N3O2/c1-4-7-14-25-19-15-17(16-10-8-9-11-18(16)22-19)20(24)21-12-13-23(5-2)6-3/h8-11,15H,4-7,12-14H2,1-3H3,(H,21,24)
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = PUFQVTATUTYEAL-UHFFFAOYSA-N
}}
 
 
 
<!--Mechanism of Action-->
|mechAction=  


<!--Structure-->
<!--Structure-->
|structure=* Active ingredients - Dibucaine 1%
|structure=* Active ingredients - Dibucaine 1%
Inactive Ingredients  
* Inactive Ingredients - acetone sodium bisulfite, lanolin, light mineral oil, purified water, white petrolatum  
 
acetone sodium bisulfite, lanolin, light mineral oil, purified water, white petrolatum  




Line 128: Line 182:


<!--How Supplied-->
<!--How Supplied-->
|howSupplied=*
|howSupplied=
|storage=store at controlled room temperature 20 degrees to 25 degrees c
|storage=store at controlled room temperature 20 degrees to 25 degrees c
|packLabel=====Ingredients and Appearance====
|packLabel=====Ingredients and Appearance====
Line 138: Line 192:
|fdaPatientInfo=to secure child resistant cap; screw cap tightly. Then turn cap in opposite direction.  
|fdaPatientInfo=to secure child resistant cap; screw cap tightly. Then turn cap in opposite direction.  
If clicking sound is not heard, repeat procedure.  
If clicking sound is not heard, repeat procedure.  
- see crimp of tube for lot number and expiration date  
- see crimp of tube for lot number and expiration date
|alcohol=* Alcohol-{{PAGENAME}} interaction has not been established. Talk to your doctor about the effects of taking alcohol with this medication.
|alcohol=* Alcohol-{{PAGENAME}} interaction has not been established. Talk to your doctor about the effects of taking alcohol with this medication.


Line 148: Line 202:
|drugShortage=
|drugShortage=
}}
}}
{{PillImage
|fileName=No image.jpg
}}
{{LabelImage
|fileName={{PAGENAME}}11.png
}}
{{LabelImage
|fileName={{PAGENAME}}11.png
}}
<!--Pill Image-->






<!--Label Display Image-->


<!--Category-->


{{Vasoprotectives}}
{{Antipruritics}}
{{local anesthetics}}
{{dermatologic-drug-stub}}
{{nervous-system-drug-stub}}


 
[[Category:Local anesthetics]]
 
[[Category:Quinolines]]
<!--Category-->
[[Category:Phenol ethers]]
 
[[Category:Amides]]
[[Category:Drug]]
[[Category:Drug]]

Latest revision as of 19:51, 18 August 2015

Dibucaine
Adult Indications & Dosage
Pediatric Indications & Dosage
Contraindications
Warnings & Precautions
Adverse Reactions
Drug Interactions
Use in Specific Populations
Administration & Monitoring
Overdosage
Pharmacology
Clinical Studies
How Supplied
Images
Patient Counseling Information
Precautions with Alcohol
Brand Names
Look-Alike Names

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Rabin Bista, M.B.B.S. [2]

Disclaimer

WikiDoc MAKES NO GUARANTEE OF VALIDITY. WikiDoc is not a professional health care provider, nor is it a suitable replacement for a licensed healthcare provider. WikiDoc is intended to be an educational tool, not a tool for any form of healthcare delivery. The educational content on WikiDoc drug pages is based upon the FDA package insert, National Library of Medicine content and practice guidelines / consensus statements. WikiDoc does not promote the administration of any medication or device that is not consistent with its labeling. Please read our full disclaimer here.
NOTE: Most over the counter (OTC) are not reviewed and approved by the FDA. However, they may be marketed if they comply with applicable regulations and policies. FDA has not evaluated whether this product complies.

Overview

Dibucaine is a Local analgesic ointment that is FDA approved for the treatment of pain and itching due to hemorrhoids or other anorectal disorders, Sunburn, minor burns, minor cuts. Common adverse reactions include unusual warmth or flushing of skin, Contact dermatitis, Photosensitivity.

Adult Indications and Dosage

FDA-Labeled Indications and Dosage (Adult)

Indications

  • temporarily relieves pain and itching due to:

Dosage

Directions
  • if possible clean the affected area with mild soap and warm water and rinse thoroughly
  • gently dry by patting or blotting with toilet tissue or a soft cloth before applying
  • Adults and children 12 and over - apply externally to the affected area up to 3 to 4 times a day.

Off-Label Use and Dosage (Adult)

Guideline-Supported Use

There is limited information regarding Off-Label Guideline-Supported Use of Dibucaine in adult patients.

Non–Guideline-Supported Use

There is limited information regarding Off-Label Non–Guideline-Supported Use of Dibucaine in adult patients.

Pediatric Indications and Dosage

FDA-Labeled Indications and Dosage (Pediatric)

  • Children under 2 - 12 years of age - ask a doctor
  • Infants under 2 years of age - DO NOT USE

Off-Label Use and Dosage (Pediatric)

Guideline-Supported Use

There is limited information regarding Off-Label Guideline-Supported Use of Dibucaine in pediatric patients.

Non–Guideline-Supported Use

There is limited information regarding Off-Label Non–Guideline-Supported Use of Dibucaine in pediatric patients.

Contraindications

There is limited information regarding Dibucaine Contraindications in the drug label.

Warnings

  • For external use only.
  • Allergy alert - certain persons san develop allergic reactions to ingredients in this product
  • Do not use
  • in or near the eyes
  • do not get into the eyes
  • in infants under 2 years of age
  • in large quantities, particularly over raw surfaces or blistered areas
  • do not put this product into rectum by using fingers or any mechanical device
  • Stop use and ask a doctor if
  • condition worsens, or does not improve within 7 days
  • the symptom being treated does not subside or if redness, irritation, swelling, bleeding or other symptoms develop or increase
  • If pregnant or breast feeding, as a health care professional before use
  • Keep out of the reach of children. If swallowed, get medical help or contact a Poison Control Center right away

Adverse Reactions

Clinical Trials Experience

There is limited information regarding clinical trial experience of Dibucaine in the drug label.

Postmarketing Experience

Drug Interactions

There is limited information regarding Dibucaine Drug Interactions in the drug label.

Use in Specific Populations

Pregnancy

Pregnancy Category (FDA):

  • If pregnant or breast feeding, as a health care professional before use


Pregnancy Category (AUS):

  • Australian Drug Evaluation Committee (ADEC) Pregnancy Category

There is no Australian Drug Evaluation Committee (ADEC) guidance on usage of Dibucaine in women who are pregnant.

Labor and Delivery

There is no FDA guidance on use of Dibucaine during labor and delivery.

Nursing Mothers

  • If pregnant or breast feeding, as a health care professional before use

Pediatric Use

There is no FDA guidance on the use of Dibucaine with respect to pediatric patients.

Geriatic Use

There is no FDA guidance on the use of Dibucaine with respect to geriatric patients.

Gender

There is no FDA guidance on the use of Dibucaine with respect to specific gender populations.

Race

There is no FDA guidance on the use of Dibucaine with respect to specific racial populations.

Renal Impairment

There is no FDA guidance on the use of Dibucaine in patients with renal impairment.

Hepatic Impairment

There is no FDA guidance on the use of Dibucaine in patients with hepatic impairment.

Females of Reproductive Potential and Males

There is no FDA guidance on the use of Dibucaine in women of reproductive potentials and males.

Immunocompromised Patients

There is no FDA guidance one the use of Dibucaine in patients who are immunocompromised.

Administration and Monitoring

Administration

Monitoring

There is limited information regarding Monitoring of Dibucaine in the drug label.

IV Compatibility

There is limited information regarding IV Compatibility of Dibucaine in the drug label.

Overdosage

  • Keep out of the reach of children. If swallowed, get medical help or contact a Poison Control Center right away

Pharmacology

Template:Px
Dibucaine
Systematic (IUPAC) name
2-butoxy-N-[2-(diethylamino)ethyl]quinoline-4-carboxamide
Identifiers
CAS number 85-79-0
ATC code C05AD04 D04AB02 (WHO) N01BB06 (WHO) S01HA06 (WHO) S02DA04 (WHO)
PubChem 3025
DrugBank DB00527
Chemical data
Formula Template:OrganicBox atomTemplate:OrganicBox atomTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBox atomTemplate:OrganicBoxTemplate:OrganicBox atomTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBox 
Mol. mass 343.463 g/mol
SMILES eMolecules & PubChem
Pharmacokinetic data
Bioavailability ?
Metabolism ?
Half life ?
Excretion ?
Therapeutic considerations
Pregnancy cat.

?

Legal status

OTC(US)

Routes topical, intravenous (equine euthanasia)

Mechanism of Action

There is limited information regarding Dibucaine Mechanism of Action in the drug label.

Structure

  • Active ingredients - Dibucaine 1%
  • Inactive Ingredients - acetone sodium bisulfite, lanolin, light mineral oil, purified water, white petrolatum

Pharmacodynamics

There is limited information regarding Pharmacodynamics of Dibucaine in the drug label.

Pharmacokinetics

There is limited information regarding Pharmacokinetics of Dibucaine in the drug label.

Nonclinical Toxicology

There is limited information regarding Nonclinical Toxicology of Dibucaine in the drug label.

Clinical Studies

There is limited information regarding Clinical Studies of Dibucaine in the drug label.

How Supplied

There is limited information regarding Dibucaine How Supplied in the drug label.

Storage

store at controlled room temperature 20 degrees to 25 degrees c

Images

Drug Images

{{#ask: Page Name::Dibucaine |?Pill Name |?Drug Name |?Pill Ingred |?Pill Imprint |?Pill Dosage |?Pill Color |?Pill Shape |?Pill Size (mm) |?Pill Scoring |?NDC |?Drug Author |format=template |template=DrugPageImages |mainlabel=- |sort=Pill Name }}

Package and Label Display Panel

Ingredients and Appearance

This image is provided by the National Library of Medicine.

{{#ask: Label Page::Dibucaine |?Label Name |format=template |template=DrugLabelImages |mainlabel=- |sort=Label Page }}

Patient Counseling Information

to secure child resistant cap; screw cap tightly. Then turn cap in opposite direction. If clicking sound is not heard, repeat procedure. - see crimp of tube for lot number and expiration date

Precautions with Alcohol

  • Alcohol-Dibucaine interaction has not been established. Talk to your doctor about the effects of taking alcohol with this medication.

Brand Names

Look-Alike Drug Names

There is limited information regarding the look alike names.

Drug Shortage Status

Price

References

The contents of this FDA label are provided by the National Library of Medicine.

  1. "Dibucaine".




Template:Vasoprotectives Template:Antipruritics

Template:Dermatologic-drug-stub Template:Nervous-system-drug-stub